Related Experiment Video
Updated: Jun 13, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
[Association between plasma adiponectin level and in-stent restenosis after coronary stenting]
Insights
Lower plasma adiponectin levels are associated with increased in-stent restenosis after coronary stenting. This finding may help predict restenosis risk in patients with coronary heart disease undergoing stent implantation.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Interventional Cardiology
Context:
- Coronary heart disease (CHD) poses a significant health burden.
- In-stent restenosis (ISR) is a major complication following coronary stenting.
- Identifying predictors of ISR is crucial for improving patient outcomes.
Purpose:
- To investigate the relationship between plasma adiponectin levels and the occurrence of in-stent restenosis.
- To determine if adiponectin can serve as a biomarker for ISR in patients after coronary stenting.
Summary:
- This study analyzed 119 patients undergoing coronary stenting, comparing 65 without ISR (Group A) to 54 with ISR (Group B).
- Plasma adiponectin levels were significantly lower in patients with ISR (Group B) compared to those without (Group A).
- Quantitative coronary angiography at 9-12 months revealed a higher minimum lumen diameter and lower restenosis rate in Group A, correlating with higher adiponectin levels.
Impact:
- Lower plasma adiponectin levels may indicate an increased risk of in-stent restenosis.
- Adiponectin could potentially be utilized as a predictive biomarker for ISR.
- Findings contribute to a better understanding of the pathophysiology of ISR and may inform future preventative strategies.
Objective:
The purpose of the present study was to identify the relationship between the plasma level of adiponectin and in-stent restenosis of patients with coronary heart disease after coronary stenting.
Method:
The study population comprised 119 individuals (92 men) who underwent stent implantation, including 65 subjects without in-stent restenosis (group A) and 54 patients with in-stent restenosis (group B). The level of plasma adiponectin was measured using ELISA. Coronary angiography was performed immediately before and after implanting stent and 9 - 12 months later.
Results:
Baseline characteristics including drug use after PCI were similar between the groups. The rate of implanting bare metal stent is 8 (12.31%) and 6 (11.11%), TAXUS drug-eluting stent is 11 (16.92%) and 10 (18.52%) and CYPHER drug-eluting stent is 46 (70.77%) and 38 (70.37%) respectively (all P > 0.05). Plasma level of adiponectin in patient of group A was significantly higher than that in group B [(15.16 +/- 5.02) mg/L vs. (10.01 +/- 4.93) mg/L, P < 0.05]. The quantitative coronary angiography (QCA) showed that lesion length was similar between groups [(15.82 +/- 6.67) mm vs. (13.40 +/- 4.20) mm, P > 0.05], minimum lumen diameter (MLD) and stenosis rate were also similar before and after implanting stent (P > 0.05) and acute gain was (1.48 +/- 0.65) mm vs. (1.19 +/- 0.37) mm (P > 0.05). MLD was higher in group A than that in group B [(2.55 +/- 0.53) mm vs. (0.57 +/- 0.60) mm, P < 0.01] at 9 - 12 months follow up. Restenosis rate [(24.2 +/- 11.2)% vs.(81.0 +/- 19.1)%, P < 0.01] and late lumen loss [(0.50 +/- 0.34) mm vs. (1.60 +/- 0.54) mm, P < 0.01] were lower in group A than in group B.
Conclusions:
The lower plasma adiponectin level might be associated with in-stent restenosis after coronary stenting.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Atherosclerosis III: Management